tbuckley/cabot-search huggingface dataset:
S81 Oncostatin m is a novel mediator of human pulmonary endothelial chemokine and protease activity in the lung in ARDS
Authors: M Fitzgerald, DF McAuley, CM O’Kane
Journal: Thorax (2016)

<h3>Background</h3> In the acute respiratory distress syndrome (ARDS) predominantly neutrophil mediated inflammation causes injury to the alveolar epithelial and capillary endothelial junction. Oncostatin M (OSM) is a pleiotropic IL-6 cytokine, upregulated in the lung in ARDS. We have shown that OSM synergises with other cytokines to drive IL-8 secretion from alveolar epithelial cells, but its role in driving endothelial injury is unknown. CXCL5 is an OSM-dependent neutrophil chemokine that is implicated in driving endothelial cell-mediated neutrophil recruitment to the lung in animal models of pneumonia. We hypothesised that OSM stimulates the production of neutrophilic chemokines and proteases by the alveolar endothelium in patients with ARDS. <h3>Methods</h3> Immunocytochemistry and western blotting were performed respectively on fixed and lysed human pulmonary microvascular endothelial cells (HPMECs). The cells were stimulated with OSM ± TNF-alpha, and chemokine (CXCL5/8) and matrix metalloproteinase (MMP) production measured by ELISA. Conditioned media from LPS-stimulated human macrophages (CoMLPS), pre-incubated with inhibitory antibodies to OSM, was used to stimulate HPMECs, and the effect on endothelial protease and chemokine production measured. <h3>Results</h3> The OSM receptor (OSMR) was detected in HPMECs at immunocytochemistry and western blot of cell lysates. Stimulation of HPMECs with recombinant OSM and TNF- α increased CXCL5 from 32 (5.6) to 739 (166) pg/m, CXCL8 from 2.2(0.4) to 11.0 (2.9) ng/ml, and MMP-3 from 35.3 (1.8) to 57.6 (10.7) pg/ml. Concentrations of the endogenous inhibitors of MMPs, i.e. Tissue Inhibitors of Metalloproteinases (TIMPs)-2 were decreased from 25.2 (1.7) to 13.7 (3.2) ng/ml while concentrations of TIMP-1 were unchanged. CXCL5 levels were decreased from 13.2 (2.2) to 6.5 (1.1) ng/ml and levels of MMP-3 were decreased from 78.7 (16.6) to 41.4 (9.4) pg/ml from HPMEC stimulated with CoMLPS + inhibitory Ab to OSM. Interestingly, CXCL8 was not significantly abrogated by OSM neutralisation. CXCL5 was increased in BALF from 20.7 (1.9) to 392.5 (53.5) pg/ml from patients with ARDS (Figure 1). <h3>Conclusions</h3> OSM drives induction of neutrophil chemokines, particularly CXCL5, and proteases by the alveolar endothelium. Targeted therapeutic inhibition of OSM may down-regulate neutrophil recruitment and MMP activity in ARDS, and will be further explored in an ex vivo human lung model.
Megakaryocytes Possess a Functional Intrinsic Apoptosis Pathway That Must Be Restrained In Order to Survive and Produce Platelets
Authors: Emma C Josefsson, Chloé James, Katya J Henley, Marlyse A Debrincat, Kelly L Rogers, Mark R Dowling, Michael J White, Elizabeth A Kruse, Sarah Ellis, Paquita Nurden, Cassandra J Vandenberg, Kylie D Mason, A O'Reilly Lorraine, Donald Metcalf, Andrew W Roberts, David CS Huang, Benjamin T Kile
Journal: Blood (2010)
Treatment Does Not Correlate with Quality of Life in Children with Immune Thrombocytopenic Purpura: Results From the KIT International Cross-Cultural Validation Study.
Authors: Robert Klaassen, John D. Grainger, Arne Riedlinger, Victor S. Blanchette, Tricia Burke, Estela Citrin, Gustavo Dufort y Alvarez, Petronella Rachieru, Josué Rakotonjanahary, Gerhard Gaedicke, Cindy D. Wakefield, Nancy L. Young
Journal: Blood (2009)
P30 An evaluation of the use of quality-of-life (qol) scores in pulmonary arterial hypertension
Authors: SC Woolcock, PA Corris
Journal: Thorax (2016)

<h3>Introduction</h3> Pulmonary Arterial Hypertension (PAH) is a severe, progressive condition leading to increased pulmonary vascular resistance, right ventricular failure and death. PAH is associated with poor prognosis and WHO functional class (FC) is strongly predictive of mortality. Living with PAH has significant physical, psychological and social impact on the lives of patients and carers. Symptoms of depression and anxiety are common and may contribute to poor quality of life (QOL) and social isolation. Although QOL scores have been developed and validated in PAH, the psychological impact of living with PAH is often overlooked. Current guidelines advocate appropriate psychological and social support for patients, however, no formal recommendations exist currently to guide clinicians with regard to the timing and involvement of appropriately skilled professionals. <h3>Methods</h3> QOL questionnaire data (Emphasis-10) was collected retrospectively from PAH patients attending routine appointments at PAH nurse and physician-led clinics over a 5 week period (June–July 2016). <h3>Results</h3> 56 patients Median age: 62 (31–88) Sex: Male 17 (30%): Female 39 (70%) WHO FC: II: 24 (43%) III: 26 (46%) IV: 6 (11%) Aetiology: Familial: 2 (3%) Portal hypertension: 2 (3%) Connective tissue disease: 8 (14%) Congenital heart disease: 14 (25%) Idiopathic (IPAH): 19 (34%) CTEPH: 12 (21%) Emphasis 10 score (50): FC II: 15 (median), 1–35 (range). FC III: 31 (median), 2 – 50 (range). FC IV: 33 (median), 10–44 (range) <h3>Conclusion</h3> Anxiety and depression are common in PAH and can lead to reduced physical and social functioning and poor QOL. The management of physical and psychological symptom burden is important for holistic patient care. Patients with advanced PAH are known to have significantly impaired QOL and this is supported by our data. Whilst QOL scores are recommended in current guidelines and frequently used in clinical practice, there remains uncertainty around the identification and referral of suitable patients to colleagues skilled in psychological interventions and the role for supportive (palliative) care. Our data shows a wide variation in QOL scores within each FC. This shows that psychological support should be considered on an individual patient basis and not only reserved for patients with a poor FC.
P193 Early non-invasive ventilation versus standard oxygen therapy in immunocompromised patients with respiratory failure: a meta-analysis
Authors: RV Villalobos, UK Gopez, K Flores
Journal: Thorax (2016)

<h3>Background and aims</h3> Respiratory failure is common in immunocompromised patients. Intubation and mechanical ventilation (MV) is the mainstay of treatment but is associated with increased risk of pneumonia and other complications. Non-invasive ventilation (NIV) is an alternative to MV in a select group of patients and aims to avoid the complications of MV. In these patients, we performed a meta-analysis on the effect of early NIV versus conventional oxygen therapy in reducing intubation rates and other important clinical outcomes. <h3>Methods</h3> We performed an extensive online and unpublished data search for relevant studies that met the inclusion criteria. We included randomised controlled trials that used early NIV versus conventional oxygen therapy in immunocompromised patients with respiratory failure. Risk of bias and acceptability assessment were independently performed by the authors. The primary outcome of interest was intubation and MV rate.The secondary outcomes were ICU and all-cause mortality, ICU length of stay and duration of mechanical ventilation. <h3>Results</h3> Four studies with a total of 553 patients met the criteria for inclusion and were included in the analysis. Patients given NIV were 38% less likely to be intubated vs. those given oxygen, RR 0.62 (95% CI: 0.42, 0.93); however, this result is significantly heterogenous. After sensitivity analysis, results showed 48% less likelihood of intubation and mechanical ventilation in the group treated with NIV, RR 0.52 (95% CI: 0.35, 0.77). Patients on NIV had 1.18days less stay in the ICU vs. oxygen group (95% CI: −1.84, −0.5 days). There was no statistically significant decrease in all-cause mortality between the two groups, RR 0.84 (95% CI: 0.63, 1.13), but this effect is heterogenous. After another sensitivity analysis performed specifically for this outcome, results showed a 25% significant reduction in all cause mortality in patients given NIV vs. oxygen therapy, RR 0.75 (95% CI: 0.58, 0.96). There is no difference in the duration of mechanical ventilation between groups. <h3>Conclusions</h3> In immunocompromised patients with respiratory failure, early NIV reduced intubation rates and decreased all-cause mortality and length of ICU stay compared to standard oxygen therapy.
Cancer incidence and mortality risks in a large US Barrett's oesophagus cohort
Authors: Michael B Cook, Sally B Coburn, Jameson R Lam, Philip R Taylor, Jennifer L Schneider, Douglas A Corley
Journal: Gut (2017)

Barrett's oesophagus (BE) increases the risk of oesophageal adenocarcinoma by 10-55 times that of the general population, but no community-based cancer-specific incidence and cause-specific mortality risk estimates exist for large cohorts in the USA.
P1.03-002 Can We Discriminate between Different Subtypes of Non-Small Cell Cancer Patients Based on Plasma Metabolic Fingerprint?
Authors: Michal Ciborowski, Kaolina Pietrowska, Joanna Kisluk, Paulina Samczuk, Miroslaw Kozlowski, Jacek Niklinski, Adam Kretowski
Journal: Journal of Thoracic Oncology (2017)
P2.02-021 Extracranial Progression (ePD) after Chemoradiotherapy (CRT) for Stage III NSCLC: Does the Chemotherapy Regimen Matter?
Authors: Lizza Hendriks, Anita Brouns, Mohammad Amini, Wilma Uyterlinde, Robin Wijsman, Jan Bussink, Bonne Biesma, S. Bing Oei, Jos Stigt, Gerben Bootsma, José Belderbos, Dirk De Ruysscher, Michel Van Den Heuvel, Anne-Marie Dingemans
Journal: Journal of Thoracic Oncology (2017)
Adverse Health Effects Associated with Living in a Former Methamphetamine Drug Laboratory — Victoria, Australia, 2015
Authors: Jackie Wright, Michaela E. Kenneally, John W. Edwards, G. Stewart Walker
Journal: MMWR Morbidity and Mortality Weekly Report (2017)

The manufacture of methamphetamine in clandestine drug laboratories occurs in various locations, including residential houses and apartments. Unlike the controlled manufacture of chemicals and drugs, clandestine manufacture results in the uncontrolled storage, use, generation, and disposal of a wide range of chemicals and the deposit of methamphetamine drug residues on indoor surfaces (1). These residues have been found at high levels on porous and nonporous surfaces and have been shown to persist for months to years (1). Persons exposed to these environments often have poorly defined exposures and health effects. It is commonly assumed that these levels of exposure are low compared with those related to illicit drug use or therapeutic use of amphetamine-based drugs for managing behavioral issues such as attention deficit hyperactivity disorder (2). In 2015, a family that was unknowingly exposed to methamphetamine residues in a house in Australia was found to have adverse health effects and elevated methamphetamine levels in hair samples, highlighting the potential for public health risks for persons who might live in methamphetamine-contaminated dwellings. This case study highlights the importance of the identification and effective decontamination of former clandestine drug laboratories.
P2.02-061 Role of MMP-2-1306C/T in Onset of Hematological Toxicity in Lung Cancer Patients Receiving First Line Platinum Based Therapy
Authors: Antonella Daniele, Rosa Divella, Domenico Galetta, Ines Abbate, Porzia Casamassima, Antonio Fabio Logroscino, Elisabetta Sara Montagna, Annamaria Catino
Journal: Journal of Thoracic Oncology (2017)
Comparison of Efficacy of Preventive and Therapeutic Vaccines Targeting the N Terminus of β-Amyloid in an Animal Model of Alzheimer’s Disease
Authors: Irina Petrushina, Hayk Davtyan, Armine Hovakimyan, Arpine Davtyan, Giselle F. Passos, David H. Cribbs, Anahit Ghochikyan, Michael G. Agadjanyan
Journal: Molecular Therapy (2017)

Previously, we reported that Alzheimer's disease (AD) epitope vaccines (EVs) composed of N-terminal β-amyloid (Aβ42) B cell epitope fused with universal foreign T helper (Th) epitope(s) were immunogenic, potent, and safe in different amyloid precursor protein (APP) transgenic mice with early AD-like pathology. However, developing an effective therapeutic vaccine is much more challenging, especially when a self-antigen such as Aβ42 is a target. Here, we directly compare the efficacy of anti-Aβ42 antibodies in Tg2576 mice with low or high levels of AD-like pathology at the start of immunizations: 6–6.5 months for preventive vaccinations and 16–19 months for therapeutic vaccinations. EV in a preventive setting induced high levels of anti-Aβ antibodies, significantly reducing pathologic forms of Aβ in the brains of Tg2576 mice. When used therapeutically for immunesenescent Tg2576 mice, EV induced low levels of antibodies not sufficient for clearing of AD-like pathology. Separately, we demonstrated that EV was also not effective in 11–11.5-month-old Tg2576 mice with moderate AD-like pathology. However, we augmented the titers of anti-Aβ antibodies in transgenic (Tg) mice of the same age possessing the pre-existing memory Th cells and detected a significant decrease in diffuse and core plaques in cortical regions compared to control animals along with improved novel object recognition performance. Previously, we reported that Alzheimer's disease (AD) epitope vaccines (EVs) composed of N-terminal β-amyloid (Aβ42) B cell epitope fused with universal foreign T helper (Th) epitope(s) were immunogenic, potent, and safe in different amyloid precursor protein (APP) transgenic mice with early AD-like pathology. However, developing an effective therapeutic vaccine is much more challenging, especially when a self-antigen such as Aβ42 is a target. Here, we directly compare the efficacy of anti-Aβ42 antibodies in Tg2576 mice with low or high levels of AD-like pathology at the start of immunizations: 6–6.5 months for preventive vaccinations and 16–19 months for therapeutic vaccinations. EV in a preventive setting induced high levels of anti-Aβ antibodies, significantly reducing pathologic forms of Aβ in the brains of Tg2576 mice. When used therapeutically for immunesenescent Tg2576 mice, EV induced low levels of antibodies not sufficient for clearing of AD-like pathology. Separately, we demonstrated that EV was also not effective in 11–11.5-month-old Tg2576 mice with moderate AD-like pathology. However, we augmented the titers of anti-Aβ antibodies in transgenic (Tg) mice of the same age possessing the pre-existing memory Th cells and detected a significant decrease in diffuse and core plaques in cortical regions compared to control animals along with improved novel object recognition performance.
A Phase I-II Trial of Bortezomib Plus Oral Cyclophosphamide and Prednisone for Relapsed/Refractory Multiple Myeloma.
Authors: Donna E. Reece, Giovanni Piza, Suzanne Trudel, Mariela Pantoja, Christine Chen, Joseph R. Mikhael, Vishal Kukreti, Keith Stewart
Journal: Blood (2006)
Additional Decitabine Did Not Improve Outcomes of Elder Acute Myeloid Leukemia Patients Based on Microtransplantation with Cytarabine and Anthracycline Chemotherapy
Authors: Kaixun Hu, Yajing Huang, Huisheng Ai, Mei Guo, Yu Changlin, Qiao Jianhui, Qiyun Sun, Zheng Dong, Hongli Zuo, Bo CAI, Xuliang Shen
Journal: Blood (2015)
P3.02b-121 Targeting miR-200c/LIN28B Axis in Acquired EGFR-TKI Resistance Non-Small Cell Lung Cancer Cells Harboring EMT Features
Authors: Kazuhiko Shien, Hiroki Sato, Ken Suzawa, Shuta Tomida, Shinsuke Hashida, Hiromasa Yamamoto, Junichi Soh, Hidejiro Torigoe, Kei Namba, Mototsugu Watanabe, Hiroaki Asano, Kazunori Tsukuda, Shinichiro Miyoshi, Shinichi Toyooka
Journal: Journal of Thoracic Oncology (2017)
P2 Incorporation of an in-depth thoracic ultrasound assessment into routine pre-procedural evaluation of patients with pleural effusions
Authors: JP Corcoran, A Talwar, RJ Hallifax, I Psallidas, JM Wrightson, NM Rahman
Journal: Thorax (2016)

<h3>Background</h3> Pleural disease affects 1 in 300 people annually; furthermore, the incidence of malignant pleural effusion (MPE) is increasing with over 40,000 cases each year in the UK alone. A significant minority of patients will have non-expandable lung (NEL) secondary to underlying disease. At present, there is no way of pre-emptively identifying these individuals; with current strategies such as pleural manometry requiring invasive intervention. Early recognition of patients with NEL would streamline care and allow them to be offered appropriate treatment; i.e., indwelling pleural catheter insertion rather than chemical pleurodesis. Recent research<sup>1</sup> has described the novel use of thoracic ultrasound (TUS) to identify NEL by assessing mobility and compliance of the atelectatic lung within an effusion. However, this work has not been replicated and was delivered by researchers with expertise and facilities not used by or available to most practitioners. <h3>Method</h3> We incorporated an in-depth TUS protocol into the pre-procedural assessment of patients undergoing intervention for suspected MPE, where ≥500 mL of fluid was expected to be drained. TUS images were acquired by two chest physicians with RCR level 1 competence or above. Data recorded included size and characteristics of the effusion; presence of pleural thickening; behaviour of the lung and diaphragm; and M-mode displacement with cardiac impulse of the atelectatic lung during breath hold manoeuvres. NEL was determined using post-drainage imaging (chest X-ray and/or CT) and clinical notes. <h3>Results</h3> 34 patients underwent in-depth TUS evaluation (Table 1). Image acquisition and measurements took no more than five minutes in any patient. Poor M-mode displacement (&lt;0.8 mm) was only seen with NEL, whilst good movement (&gt;1.2 mm) was highly predictive of free lung. The presence of visceral thickening on TUS may also predict NEL, although there was only limited data to support this finding. <h3>Conclusion</h3> In-depth TUS assessment can be delivered and interpreted quickly in the day-case setting using widely available portable ultrasound equipment, with potential implications for patient care and non-invasive diagnosis of NEL. Further research is needed to evaluate the ability of M-mode and other TUS parameters to predict NEL and symptom response prior to invasive intervention. <h3>Reference</h3> Salamonsen MR, <i>et al</i>. Novel use of pleural ultrasound can identify malignant entrapped lung prior to effusion drainage. <i>Chest </i> 2014;<b>146</b>(5):1286–93.
MA17.03 Identifying Genomic Alteration and Inter-Tumor Heterogeneity of Multiple Primary Lung Cancers by Targeted NGS of Tumor Tissue and ctDNA
Authors: Kezhong Chen, Jingbo Zhang, Wei Chen, Fan Yang, Jiangqiao Cai, Feng Lou, Xun Wang, Mingyu Zhao, Jay Zhang, Jun Wang
Journal: Journal of Thoracic Oncology (2017)
HDL Cholesterol Efflux Capacity and Cardiovascular Events in Patients With Chronic Kidney Disease
Authors: Lucie Bauer, Sabine Kern, Kyrill S. Rogacev, Insa E. Emrich, Adam Zawada, Danilo Fliser, Akos Heinemann, Gunnar H. Heine, Gunther Marsche
Journal: Journal of the American College of Cardiology (2017)
MA14.09 Demonstrating Life Expectancy Gains with Immuno-Oncology (IO) Therapies
Authors: Jeffrey Sullivan, Alison Sexton Ward, Beata Korytowsky, Desi Peneva, Jennifer Benner, Darius Lakdawalla, Bjorn Bolinder, Robert Figlin, Anupam Jena
Journal: Journal of Thoracic Oncology (2017)
Role of Bortezomib in the Treatment of Multiple Myeloma - First Results from a Representative Multicentre Treatment Survey in Germany (GER).
Authors: Ralf Angermund, W. Knauf, M. Freund, M. R. Nowrousian, H. Einsele, H. Goldschmidt, W. E. Berdel, W. Poenisch, C. Straka, L. Kellermann, S. Bammer
Journal: Blood (2005)
P1.07-001 A Phase II Study of Etirinotecan Pegol (NKTR-102), a Topoisomerase-I lnhibitor Polymer Conjugate, in Small Cell Lung Cancer
Authors: Hongbin Chen, Grace Dy, Adrienne Groman, William Brady, Saad Jamshed, Peter Bushunow, Noelle Brunsing, Alex Adjei
Journal: Journal of Thoracic Oncology (2017)
Comparison of Immunohystochemical (IHC) Expression Profile and Prognosis in 98 Patients with Diffuse Large B Cell Non-Hodgkin’s Lymphoma (DLBCL) with and without Human Immunodeficiency Virus (HIV) Infection.
Authors: Blanca Xicoy, Josep-Maria Ribera, Mireia Morgades, Jose-Luis Mate, Gustavo Tapia, Jose-Tomas Navarro, Tatiana Ruiz, Aurelio Ariza, Evarist Feliu
Journal: Blood (2007)
P1.07-021 Impact on Survival of High Dose Consolidative Thoracic Radiotherapy in Extensive Stage Small Cell Lung Cancer
Authors: Josep Jové, Anabel Mañes, Yolanda Luis, Geovanna Perez, Rosa Ballester, Beatriz Gutierrez, Victoria Tuset, Monica Caro, Alex Melero, Jaume Molero, Isabel Planas, Ernest Luguera, Ana Alvarez, Salva Villà, Antonio Arellano
Journal: Journal of Thoracic Oncology (2017)
Laparoscopic Roux-en-Y gastric bypass in adolescents with severe obesity (AMOS): a prospective, 5-year, Swedish nationwide study
Authors: Torsten Olbers, Andrew J Beamish, Eva Gronowitz, Carl-Erik Flodmark, Jovanna Dahlgren, Gustaf Bruze, Kerstin Ekbom, Peter Friberg, Gunnar Göthberg, Kajsa Järvholm, Jan Karlsson, Staffan Mårild, Martin Neovius, Markku Peltonen, Claude Marcus
Journal: The Lancet Diabetes & Endocrinology (2017)
Treating nonalcoholic steatohepatitis in children: Not a cinch task
Authors: Naim Alkhouri, Ariel E. Feldstein
Journal: Hepatology (2017)

1Department of Pediatric Gastroenterology and HepatologyCleveland ClinicClevelandOH 2Digestive Disease InstituteCleveland ClinicClevelandOH 3Department of PediatricsUniversity of California San DiegoSan DiegoCA
Novel Genomic Structural Variations in Relapsed Childhood ETV6/RUNX1 (TEL/AML1) Acute Lymphoblastic Leukemias Identified by Next Generation Sequencing
Authors: Vera Okpanyi, Christoph Bartenhagen, Michael Gombert, Sebastian Ginzel, Pina Fanny Ida Krell, Peter Husemann, Cai Chen, Vera Binder, Jutta Bradtke, Andrea Teigler-Schlegel, Silja Roettgers, Jochen Harbott, Martin Stanulla, Cornelia Eckert, Ralf Thiele, Martin Dugas, Arndt Borkhardt, Ute Fischer
Journal: Blood (2012)